

25<sup>th</sup> January, 2022

The Dy. General Manager (Listing Dept.)  
BSE Limited,  
Corporate Relationship Dept.,  
1<sup>st</sup> Floor, New Trading Ring,  
P. J. Towers, Dalal Street, Fort,  
Mumbai - 400 001  
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G. Block,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai – 400 051  
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

**Sub.: Presentation to analysts on unaudited Consolidated Financial Results for the quarter and nine months ended 31<sup>st</sup> December, 2021**

The presentation on unaudited Consolidated Financial Results for the quarter and nine months ended 31<sup>st</sup> December, 2021 to be made to analysts is enclosed for your records.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL  
VP (LEGAL) & COMPANY SECRETARY

Encl : A/a



## Q3 FY 2021-22

Revenues: Summary



# Revenue: Summary

Revenues (Rs cr)	Q3 FY22	Q3 FY21	Gr%
India	1,072	930	15%
United States	235	292	-20%
Germany	237	265	-10%
Brazil	182	173	5%
Other countries	227	191	19%
Others (Inc. CRAMS)	155	145	7%
<b>Total</b>	<b>2,108</b>	<b>1,995</b>	<b>6%</b>

